Glaxo has bird flu 'breakthrough'
UK drugs firm GlaxoSmithKline believes it has developed a vaccine for the H5N1 deadly strain of avian flu that may be capable of being mass produced by 2007.
bdnews24.com News Service
bdnews24.com
Published :
25 Jul 2006, 06:00 PM
Updated :
17 Aug 2022, 06:28 PM
London, July 26 (BDNEWS) - UK drugs firm GlaxoSmithKline believes it has developed a vaccine for the H5N1 deadly strain of avian flu that may be capable of being mass produced by 2007.
The vaccine has proved effective at two doses of 3.8 micrograms during clinical trials in Belgium, the BBC's business editor Robert Peston has learned.
It is the size of the dose that is highly significant, Glaxo explained.
Firms want the smallest effective dose so that they can get the maximum number of shots out of a quantity of vaccine.
Glaxo said that governments could order the vaccine for delivery and stockpiling in early 2007.
One of Glaxo's main rivals, the French drug company Sanofi Aventis has also been working on a vaccine.
A study published in the Lancet in May showed that Sanofi's vaccine had some effectiveness in some patients who were treated with two 7.5 microgram doses.
Drug companies are looking to develop treatments because of concerns that the H5N1 virus will combine with a human flu virus and mutate into a form which can spread between humans.
Since 2003 there have been 231 cases of avian flu in humans, resulting in 133 deaths.
BDNEWS/1431 hrs